Genetically engineered T-cells treat leukemia in babies

[Image courtesy of Caroline Davis2010, per Creative Commons 2.0 license]

Researchers in London have successfully treated leukemia in two babies, in what they are touting as the world’s first treatment of cancer using genetically engineered immune cells from donors.

Two British infants, who were 11 and 16 months old, were treated using Cellectis’ CAR T-cell product, UCART19, which is an allogeneic CAR T-cell product candidate for the treatment of chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL). They had gone through previous radiation treatments that failed before being treated with Cellectis’ UCART19.

The London’s Great Ormond Street Hospital experiments could be the first step to off-the-shelf cellular therapy using inexpensive supplies of universal cells that can be dripped into veins.

Get the full story on our sister site, Medical Design & Outsourcing.

The post Genetically engineered T-cells treat leukemia in babies appeared first on MassDevice.

from MassDevice http://ift.tt/2lrHxPL